NCT01865318View on ClinicalTrials.gov

Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Administered subcutaneously (s.c., under the skin)

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT01865318 - Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter